If Novartis's Gilenia Clears Safety Hurdle, Other Oral MS Drugs May Have An Easier Path
This article was originally published in The Pink Sheet Daily
Executive Summary
While fingolimod has a broadly similar safety profile to Merck Serono's cladribine and Teva's laquinimod, additional cardiac, pulmonary and ophthalmic adverse events may give Novartis's first mover a higher barrier to clear.
You may also be interested in...
Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market
FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.
Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market
FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.
Gilenia Advisory Committee: Is REMS + Phase IV > FDA Safety Concerns?
Novartis' oral multiple sclerosis drug Gilenia (fingolimod) faces an unusually large briefing package from FDA focused on safety concerns.